VERICEL CORPORATION Accounts Receivable
VERICEL CORPORATION (VCEL) had Accounts Receivable of $75.71 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-07-30
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $75.71M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $72.38M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $84.63M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $60.43M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $75.71M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $72.38M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $84.63M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $60.43M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $64.29M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $52.90M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $61.38M 10-K · filed 2026-02-26 |
| 2024-09-30 | $48.48M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $48.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $49.93M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $58.36M 10-K · filed 2025-02-27 |
| 2023-09-30 | $39.73M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $38.32M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $38.36M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $46.54M 10-K · filed 2024-02-29 |
| 2022-09-30 | $34.30M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $33.66M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $31.86M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $37.44M 10-K · filed 2023-02-23 |
| 2021-09-30 | $28.91M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $31.73M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $29.12M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $34.50M 10-K · filed 2022-02-24 |
| 2020-09-30 | $26.17M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $23.66M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $24.17M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $32.17M 10-K · filed 2021-02-24 |
| 2019-09-30 | $19.96M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $21.08M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $18.77M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $23.45M 10-K · filed 2020-02-25 |
| 2018-09-30 | $15.53M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $17.50M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $13.16M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $18.27M 10-K · filed 2019-02-26 |
| 2017-09-30 | $15.43M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $14.73M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $12.13M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $17.09M 10-K · filed 2018-03-05 |
| 2016-09-30 | $7.87M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $9.03M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $9.67M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $10.92M 10-K · filed 2017-03-13 |
| 2015-09-30 | $7.64M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $8.98M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $9.17M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $8.19M 10-K · filed 2016-03-14 |
| 2014-09-30 | $3.96M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $4.32M 10-Q · filed 2014-08-14 |
| 2013-12-31 | $8.00K 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |